Thursday, 21 September, 2017

Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

Melissa Porter | 17 February, 2017, 01:30

(NYSE:VRX) yearly sales estimates is $2249.135 while sales forecasts median is $2249.135. The stock was ranked as Underweight by not a single analyst while not a single analyst gave SELL rank. Valeant Pharmaceuticals International, Inc. has P/S value of 0.51 while its P/B value stands at 1.26. Stifel Nicolaus reissued a buy rating and set a $45.00 target price on shares of Valeant Pharmaceuticals International in a research report on Thursday, February 9th. Guggenheim restated a buy rating on shares of Valeant Pharmaceuticals International in a research note on Tuesday, February 7th.

The Company got Downgrade by Morgan Stanley on 15-Dec-16 from Overweight to Equal-Weight. The current share price indicate that stock is -82.55% away from its one year high and is moving 29.69% ahead of its 52-week low.

The consensus recommendation, according to Zacks Investment research, is 3.14. The company has a consensus rating of Hold and an average price target of $32.98.

On Wednesday, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock opened its trade at $16.00 and after floating in a range of $15.77 to $16.93, settled at $16.86. They now have a United States dollars 20 price target on the stock. (NYSE:VRX) has a market capitalization of 5.45 Billion. The firm has a 50-day moving average of $14.77 and a 200 day moving average of $20.39. The stock hit its 52-Week High on Feb 17, 2016 and 52-Week Low on Dec 15, 2016. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/02/16/valeant-pharmaceuticals-international-inc-vrx-receives-underperform-rating-from-mizuho.html. "(VRX) Earns Underperform Rating from Wells Fargo & Company" was originally published by BBNS and is owned by of BBNS. If you are reading this news story on another publication, it was stolen and republished in violation of United States and worldwide trademark and copyright laws. Ross (director) purchased 5,000 shares at 14.73 per share price.On Aug 12, 2016, Argeris N Karabelas (director) purchased 4,000 shares at 24.65 per share price.On Jun 13, 2016, Joseph C Papa (CEO) purchased 202,000 shares at 24.48 per share price. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

In other news, Director Thomas W. Sr. In the past 5 years, the stock showed growth of 19.56% per annum. The shares were bought at an average cost of $14.73 per share, with a total value of $73,650.00. The disclosure for this purchase can be found here.

01/30/2017 - Valeant Pharmaceuticals International, Inc. had its " rating reiterated by analysts at JP Morgan. Following the completion of the acquisition, the director now directly owns 26,822 shares of the company's stock, valued at approximately $395,088.06. Hexavest Inc. now owns 3,765,875 shares of the specialty pharmaceutical company's stock worth $92,429,000 after buying an additional 1,973,087 shares during the last quarter.

While taking a glance at financials, we can look at a number of key indicators about Valeant Pharmaceuticals International, Inc.'s (VRX). (NYSE:VRX) posted earnings of $1.55/Share in the previous quarter, as compared to earnings of $1.75/share estimated by analysts. Sumitomo Mitsui Trust Holdings Inc. boosted its stake in Valeant Pharmaceuticals International by 0.3% in the second quarter. The 52-week high of the share price is $96.62 and the 52-week low is $13.

01/20/2017 - Valeant Pharmaceuticals International, Inc. had its " rating reiterated by analysts at Deutsche Bank. World Asset Management Inc now owns 23,045 shares of the specialty pharmaceutical company's stock valued at $566,000 after buying an additional 1,910 shares during the last quarter.

01/10/2017 - Valeant Pharmaceuticals International, Inc. had its " rating reiterated by analysts at BTIG Research. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).